Tuesday, Akero Therapeutics Inc (NASDAQ: AKRO) reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to nonalcoholic steatohepatitis (NASH).
Efruxifermin was not statistically significant in topping the placebo in improving liver scarring without worsening of NASH, resulting in shares tumbling.
HC Wainwright has lowered the price target from $64 to $40, with a Buy rating.
The analyst Ed Arce says that 36 weeks is generally considered too short for most mechanisms to elicit fibrosis improvement in NASH. However, EFX has ...